Gastro-Esophageal Reflux Disease and Paroxysmal Atrial Fibrillation Ablation
Patients undergoing ablation for atrial fibrillation may be at increased risk of developing gastroesophageal reflux disease. We prospectively studied the presence of symptomatic gastroesophageal reflux disease in naïve patients who underwent atrial fibrillation ablation. Methods: The presence of typ...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/13/5/1107 |
| _version_ | 1827740960423936000 |
|---|---|
| author | Mariana Floria Diana-Elena Iov Daniela Maria Tanase Oana Bogdana Barboi Genoveva Livia Baroi Alexandru Burlacu Mihaela Grecu Radu Andy Sascau Cristian Statescu Catalina Mihai Vasile Liviu Drug |
| author_facet | Mariana Floria Diana-Elena Iov Daniela Maria Tanase Oana Bogdana Barboi Genoveva Livia Baroi Alexandru Burlacu Mihaela Grecu Radu Andy Sascau Cristian Statescu Catalina Mihai Vasile Liviu Drug |
| author_sort | Mariana Floria |
| collection | DOAJ |
| description | Patients undergoing ablation for atrial fibrillation may be at increased risk of developing gastroesophageal reflux disease. We prospectively studied the presence of symptomatic gastroesophageal reflux disease in naïve patients who underwent atrial fibrillation ablation. Methods: The presence of typical symptoms suggestive of gastroesophageal reflux disease was clinically assessed by the gastroenterologist at baseline and at 3 months after ablation. In addition to that, all patients underwent upper gastrointestinal endoscopy. Results: Seventy-five patients were included in two groups: 46 patients who underwent atrial fibrillation ablation (study group) and 29 patients without ablation (control group). Patients with atrial fibrillation ablation were younger (57.76 ± 7.66 years versus 67.81 ± 8.52 years; <i>p</i> = 0.001), predominantly male (62.2% versus 33.3%; <i>p</i> = 0.030) and with higher body mass index (28.96 ± 3.12 kg/m<sup>2</sup> versus 26.81 ± 5.19 kg/m<sup>2</sup>; <i>p</i> = 0.046). At three months after the ablation, in the study and control groups, there were 88.9% and 57.1% patients in sinus rhythm, respectively, (<i>p</i> = 0.009). Symptomatic gastroesophageal reflux disease was not more frequent in the study group (42.2% versus 61.9%; <i>p</i> = 0.220). There was no difference in terms of sinus rhythm prevalence in patients with versus without symptomatic gastroesophageal reflux disease (89.5% versus 88.5%; <i>p</i> = 0.709). Conclusion: In this small prospective study, typical symptoms suggestive of gastroesophageal reflux disease were not more frequent three months following atrial fibrillation ablation. |
| first_indexed | 2024-03-11T03:34:47Z |
| format | Article |
| id | doaj.art-c0afc3f77a1b4beb83c870497036c97c |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-11T03:34:47Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-c0afc3f77a1b4beb83c870497036c97c2023-11-18T02:08:47ZengMDPI AGLife2075-17292023-04-01135110710.3390/life13051107Gastro-Esophageal Reflux Disease and Paroxysmal Atrial Fibrillation AblationMariana Floria0Diana-Elena Iov1Daniela Maria Tanase2Oana Bogdana Barboi3Genoveva Livia Baroi4Alexandru Burlacu5Mihaela Grecu6Radu Andy Sascau7Cristian Statescu8Catalina Mihai9Vasile Liviu Drug10Department of Internal Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iași, RomaniaDepartment of Internal Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iași, RomaniaDepartment of Internal Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iași, RomaniaDepartment of Internal Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iași, RomaniaDepartment of Internal Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iași, RomaniaDepartment of Internal Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iași, RomaniaDepartment of Internal Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iași, RomaniaDepartment of Internal Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iași, RomaniaDepartment of Internal Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iași, RomaniaDepartment of Internal Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iași, RomaniaDepartment of Internal Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iași, RomaniaPatients undergoing ablation for atrial fibrillation may be at increased risk of developing gastroesophageal reflux disease. We prospectively studied the presence of symptomatic gastroesophageal reflux disease in naïve patients who underwent atrial fibrillation ablation. Methods: The presence of typical symptoms suggestive of gastroesophageal reflux disease was clinically assessed by the gastroenterologist at baseline and at 3 months after ablation. In addition to that, all patients underwent upper gastrointestinal endoscopy. Results: Seventy-five patients were included in two groups: 46 patients who underwent atrial fibrillation ablation (study group) and 29 patients without ablation (control group). Patients with atrial fibrillation ablation were younger (57.76 ± 7.66 years versus 67.81 ± 8.52 years; <i>p</i> = 0.001), predominantly male (62.2% versus 33.3%; <i>p</i> = 0.030) and with higher body mass index (28.96 ± 3.12 kg/m<sup>2</sup> versus 26.81 ± 5.19 kg/m<sup>2</sup>; <i>p</i> = 0.046). At three months after the ablation, in the study and control groups, there were 88.9% and 57.1% patients in sinus rhythm, respectively, (<i>p</i> = 0.009). Symptomatic gastroesophageal reflux disease was not more frequent in the study group (42.2% versus 61.9%; <i>p</i> = 0.220). There was no difference in terms of sinus rhythm prevalence in patients with versus without symptomatic gastroesophageal reflux disease (89.5% versus 88.5%; <i>p</i> = 0.709). Conclusion: In this small prospective study, typical symptoms suggestive of gastroesophageal reflux disease were not more frequent three months following atrial fibrillation ablation.https://www.mdpi.com/2075-1729/13/5/1107atrial fibrillationsinus rhythmgastroesophageal reflux diseaseablationesophagitis |
| spellingShingle | Mariana Floria Diana-Elena Iov Daniela Maria Tanase Oana Bogdana Barboi Genoveva Livia Baroi Alexandru Burlacu Mihaela Grecu Radu Andy Sascau Cristian Statescu Catalina Mihai Vasile Liviu Drug Gastro-Esophageal Reflux Disease and Paroxysmal Atrial Fibrillation Ablation Life atrial fibrillation sinus rhythm gastroesophageal reflux disease ablation esophagitis |
| title | Gastro-Esophageal Reflux Disease and Paroxysmal Atrial Fibrillation Ablation |
| title_full | Gastro-Esophageal Reflux Disease and Paroxysmal Atrial Fibrillation Ablation |
| title_fullStr | Gastro-Esophageal Reflux Disease and Paroxysmal Atrial Fibrillation Ablation |
| title_full_unstemmed | Gastro-Esophageal Reflux Disease and Paroxysmal Atrial Fibrillation Ablation |
| title_short | Gastro-Esophageal Reflux Disease and Paroxysmal Atrial Fibrillation Ablation |
| title_sort | gastro esophageal reflux disease and paroxysmal atrial fibrillation ablation |
| topic | atrial fibrillation sinus rhythm gastroesophageal reflux disease ablation esophagitis |
| url | https://www.mdpi.com/2075-1729/13/5/1107 |
| work_keys_str_mv | AT marianafloria gastroesophagealrefluxdiseaseandparoxysmalatrialfibrillationablation AT dianaelenaiov gastroesophagealrefluxdiseaseandparoxysmalatrialfibrillationablation AT danielamariatanase gastroesophagealrefluxdiseaseandparoxysmalatrialfibrillationablation AT oanabogdanabarboi gastroesophagealrefluxdiseaseandparoxysmalatrialfibrillationablation AT genovevaliviabaroi gastroesophagealrefluxdiseaseandparoxysmalatrialfibrillationablation AT alexandruburlacu gastroesophagealrefluxdiseaseandparoxysmalatrialfibrillationablation AT mihaelagrecu gastroesophagealrefluxdiseaseandparoxysmalatrialfibrillationablation AT raduandysascau gastroesophagealrefluxdiseaseandparoxysmalatrialfibrillationablation AT cristianstatescu gastroesophagealrefluxdiseaseandparoxysmalatrialfibrillationablation AT catalinamihai gastroesophagealrefluxdiseaseandparoxysmalatrialfibrillationablation AT vasileliviudrug gastroesophagealrefluxdiseaseandparoxysmalatrialfibrillationablation |